Examples of calcium channel blocking meds include:
Felodipine
Amlodipine (Norvasc)
Diltiazem (Cardizem, Tiazac, others)
Nifedipine (Adalat CC, Afeditab CR, Procardia)
Verapamil (Calan, Verelan)
Nisoldipine (Sular)
Isradipine
Nicardipine.
The key finding of the study was that women who have been taking these drugs for more than ten years have a risk of about 2.5 times higher risk of lobular or invasive ductal cancer compared to those who have never taken them and those who have not. they take other forms of antihypertensive drugs. In addition, the study found that the use of other classes of antihypertensive drugs, including diuretics, beta-blockers and angiotensin receptor blockers, was not associated with an increased risk of breast cancer, even when used long-term.
The study included 1,763 women aged 55 to 74 years, of whom 880 had invasive ductal cancer, 1027 invasive lobular cancer and 856 were controls. Through a series of structured questions, the researchers collected detailed data on the use of antihypertensive drugs , including the dates of start and end of use, names of medications, dosage, route of administration, use pattern and indication.
The blockers calcium channel function by regulating the entry of calcium into muscle cells, blood resistance and decreasing the oxygen demand of the heart muscle. There are some hypotheses that these drugs may increase the risk of cancer, since they inhibit programmed cell death, or apoptosis, but the evidence is insufficient.
Antihypertensive drugs are one of the most prescribed drugs in the world
Postmenopausal women treated with a calcium channel blocker for their high blood pressure have a dual risk of breast cancer, the French and international press announced after the publication of an American study in the journal JAMA. Is this result as clear as we want to say?
Calcium inhibitors have been used since the 1950s in the treatment of high blood pressure. Several classes with different modes of action exist, of which millions of prescriptions are made each year. In the United States, it is the most prescribed class of antihypertensives.
The existence of a link between calcium antagonists and cancer has been on the front pages of the medical press many times, a link each time denied by new studies . But in science everything must be regularly reevaluated, possibly targeting more specific drugs, populations or the duration of monitoring.
Calcium inhibitors and breast cancer: the link remains to be demonstrated
The existence of a link between calcium antagonists and cancer has been on the front pages of the medical press many times, a link each time denied by new studies . But in science everything must be regularly reevaluated, possibly targeting more specific drugs, populations or the duration of monitoring.
The study published in the journal JAMA targeted a population living around the city of Seattle in the United States: this is a case-control study, so retrospective, including 880 women with invasive ductal breast cancer (developed from epithelial cells lining milk-producing milk ducts), 1021 women with invasive lobular breast cancer (developed from lobules, milk-secreting units) and 856 women without breast cancer. This type of study delves into the past of patients in order to assess whether the taking of a particular treatment, in this case a calcium channel blocker, was found in more women who had breast cancer than in those who did not. having not had.
The analyzes find that taking a calcium channel blocker at the time of the study, taking a calcium channel blocker in the past, or taking a calcium channel blocker over a short period of time does not change the risk of breast cancer. whatever. However, the risk appears to be increased when calcium channel blocker therapy has lasted 10 years or more, a risk multiplied by 2.4 for invasive ductal cancer and by 2.6 for infiltrating lobular cancer. This risk persisted regardless of the class of calcium channel blocker considered but was not found for all other types of antihypertensives .
On the other hand, scientists also find that women taking at the same time an ACE inhibitor, another class of antihypertensive drug, seem to be protected from this risk of breast cancer , the risk being reduced by 30% for ductal cancers and 40% for lobular cancers: although this risk reduction is not significant, there was no increase in risk in these women with both treatments.
Should we be alarmed at these results? No, at least not at the moment. Indeed, case-control studies are never conclusive and must be supplemented by larger and more rigorous studies.
Moreover, it is important in this type of study to know who the populations really are: for example, there were only 12 patients in the control group who had taken a calcium channel blocker for 10 years or more, 27 patients in the group had ductal cancer and 32 in the group lobular cancer, a risk evaluated in fact on a population of 70 patients , the number of patients in the control group was also strangely weak. And, the more one asks for answers to this type of studies, the more the population is reduced and the results become questionable.
These results are also offset by previous studies (references below) that had not found an increased risk, some had included a much larger number of patients (324 000 for example for the study conducted by Professor Bangalore from New York).
Source
Use of Antihypertensive Medications and Breast Cancer Risk Among Women Aged 55 to 74 Years ONLINE FIRST
Christopher I. Li, MD, PhD 1 ; Janet R. Daling, PhD 1 ; Mei-Tzu C. Tang, PhD 1 ; Kara L. Haugen, MS 1 ; Peggy L. Porter, MD 1,2 ; Kathleen E. Malone
JAMA Intern Med. 2013; (): -. doi: 10.1001 / jamainternmed.2013.9071
Which, if any, antihypertensive agents cause cancer?
Singh A, Bangalore S.
Curr Opin Cardiol. 2012 Jul; 27 (4): 374-80. doi: 10.1097 / HCO.0b013e328353bc4f.
Antihypertensive drugs and risk of cancer: network meta-analyzes and trial sequential analyzes of 324,168 participants from randomized trials.
Bangalore S, Kumar S, Kjeldsen SE, Makani H, Grossman E, Wetterslev J, Gupta AK, Sever PS, Gluud C, Messerli FH.
Lancet Oncol. 2011 Jan; 12 (1): 65-82. doi: 10.1016 / S1470-2045 (10) 70260-6. Epub 2010 Nov 29.
Long-term use of antihypertensive drugs and cancer
risk TL, Elstein E, Langleben A, Suissa S.
Pharmacoepidemiol Drug Saf . Nov 2008; 17 (11): 1039-49. doi: 10.1002 / pds.1656.
A cohort study of antihypertensive medication and breast cancer among Danish women.
Fryzek JP, Poulsen AH, Lipworth L, Pedersen L, Nørgaard M, McLaughlin JK, Friis S.
Breast Cancer Res Treat. 2006 Jun; 97 (3): 231-6. Epub 2006 May 3.
Relationship between use of antihypertensive medications and risk of breast carcinoma among women ages 65-79 years.
Li CI, KE Malone, Weiss NS, DM Boudreau, Cushing-Haugen KL, Daling JR.
Cancer. 2003 Oct 1; 98 (7): 1504-13.
Relationship between drug and cancer in hypertensives in the Swedish Trial in Old Patients with Hypertension 2: a 5-year, prospective, randomized, controlled trial.
Lindholm LH, Anderson H, Ekbom T, Hansson L, Lanke J, Dahlöf B, Make U, Forsén K, Hedner T, Linjer E, Scherstén B, Wester P, Möller T
Lancet. 2001 Aug 18; 358 (9281): 539-44.
Cancer risk and mortality in calcium channel blockers. A cohort study.
Sørensen HT, Olsen JH, Mellemkjaer L, Marie A, Steffensen FH, McLaughlin JK, Baron JA
Cancer. 2000 Jul 1; 89 (1): 165-70.
Calcium channel blockers, ACE inhibitors, and the risk of cancer in hypertensive patients: a report from the Department of Hypertension Care Computing Project (DHCCP)
Stahl M, CJ Bulpitt, Palmer AJ, DG Beevers, EC Coles, Webster J
J Hum Hypertens . 2000 May; 14 (5): 299-304.
Creative Commons by Caitlinator Photo Credit
Posted in Highlights , Cancer , Cardiology , Being a woman otherwise , Gynecology , cancers of the woman , breasts Tagged antihypertensive and breast cancer , breast cancer , calcium channel blocker and breast cancer , invasive ductal carcinoma , breast cancer , cancer lobular , calcium channel blocker , calcium channel blocker and breast cancer , converting enzyme inhibitor , breast cancer prevention ,antihypertensive therapy
No comments:
Post a Comment